In the current study, we have successfully and safely applied CRISPR gene editing to disrupt GM-CSF expression in CART cells co-expressing IL6 and IL1 blockers in treating patients with refractory hematologic malignancy. The gene discussed is IL6; the disease is hematologic disorder.